lecanemab is not a you remember that? lecanemab is not a wonder drug. you remember that?drug. mavis' _ you remember that?- lecanemab is not a wonder drug. mavis' short—term i not a wonder drug. mavis' short—term memory remains badly affected. she is ureat memory remains badly affected. she is great with her childhood. she can remember— is great with her childhood. she can remember everything that went on then, _ remember everything that went on then, as _ remember everything that went on then, as she often tells us stories about— then, as she often tells us stories about that, — then, as she often tells us stories about that, but that she will forget about that, but that she will forget a conversation that you had almost immediately afterwards. lecanemab is the first drug — immediately afterwards. lecanemab is the first drug to _ immediately afterwards. lecanemab is the first drug to be _ immediately afterwards. lecanemab is the first drug to be licensed _ immediately afterwards. lecanemab is the first drug to be licensed in - immediately afterwards. lecanemab is the firs

lecanemab is a breakthrough drug that can slow down alzheimer's disease.a toxic protein in the brain, and slows cognitive decline. but the drug won't be available on the nhs in england, because it's said to be too expensive. fergus walsh reports. mavis is a rarity — one ofjust a few alzheimer's patients in the uk who are receiving lecanemab. she's been having an infusion every fortnight for several years. this was november 2022. mavis was part of a trial which showed that the drug delayed progression of early alzheimer's by around 4—6 months. do you remember, we used to watch the ducks in there? her husband is grateful for the extra time. it's enabled mavis to keep her personality. i mean, she's still our mavis. she always was bright and cheery, and she still is. we have had some wonderful years since you came on this drug, haven't we? yeah. — and some great times. and i am grateful for it too, my goodness. it's making a difference to your life, isn't it? now, i heard you had a big coffee morning this morning? _ oh, did i? do you remember that? no, i don't

lecanemab is not a wonder drug. mavis' short term memory remains badly affected. i've calculated lecanemab is likely to cost around £20,000 a year privately, but administering the drug and brain scans will probably double that which the health assessment body, nice says does not represent value for money. you hold that for me, please? right. and i'll use this on your left, 0k? there are dozens of similar drugs going through clinical trials. alzheimer's charities want the nhs to get ready for this new era of treatment. this is a defining moment for alzheimer's disease and gives us real hope for the future. but we have some big challenges ahead because the key to getting access to this treatment, or any potential future treatment, will be getting an early and accurate diagnosis. and we're nowhere near that at the moment. lecanemab can cause brain swelling and bleeding, so patients need careful monitoring. despite the risks and its modest benefits, many alzheimer's researchers regard lecanemab as a turning point because it shows this dreaded disease has its weaknesse

lecanemab is not a wonder drug. mavis' short—term memory remains badly affected. can remember everything that went on then, and she often tells us stories about that — but that she will forget a conversation that you had almost immediately afterwards. lecanemab is the first drug to be licensed in the uk which can slow the progress of alzheimer's, albeit modestly. it works by clearing a rogue protein which builds up in the brains of alzheimer's patients. i've calculated that lecanemab is likely to cost around £20,000 a year privately — but administering the drug and brain scans will probably double that, which the health assessment body nice says does not represent value for money. hold that for me, please. and i'll use this on your left, 0k? there are dozens of similar drugs going through clinical trials. alzheimer's charities want the nhs to get ready for this new era of treatment. this is a defining moment for alzheimer's disease and gives us real hope for the future. but we have some big challenges ahead, because the key to getting access to this treatment, or

lecanemab is not a wonder drug. mavis' short term memory remains badly affected.ve calculated lecanemab is likely to cost around £20,000 a year privately, but administering the drug and brain scans will probably double that which the health assessment body, nice says does not represent value for money. you hold that for me, please? right. and i'll use this on your left, ok? there are dozens of similar drugs going through clinical trials. alzheimer's charities want the nhs to get ready for this new era of treatment. this is a defining moment for alzheimer's disease and gives us real hope for the future. but we have some big challenges ahead because the key to getting access to this treatment, or any potential future treatment, will be getting an early and accurate diagnosis. and we're nowhere near that at the moment. lecanemab can cause brain swelling and bleeding, so patients need careful monitoring. despite the risks and its modest benefits, many alzheimer's researchers regard lecanemab as a turning point because it shows this dreaded disease has its weaknesses a

i think the main point about lecanemab is that it's enabled mavis to keep her personality. she's still our mavis, and she always was bright and cheery, and she still is. we've had some wonderful years since you came on this drug, haven't we? yeah. — and some great times. and i'm gratefulfor it, too, my goodness. you know, it's making a difference to your life, isn't it? that's fine, yeah. mavis receives the drug every two weeks by infusion. trials showed it can slow cognitive decline by about a quarter in patients with early stage alzheimer's. now, i heard that you had a big coffee morning this morning. 0h, did i? do you remember that? no, i don't. but mavis's short—term memory remains badly affected. she's great with her childhood. she can remember everything that went on then, and she often tells us stories about that. but she'll forget a conversation that you had almost immediately afterwards. lecanemab is the first drug to be licensed in the uk which can slow the progress of alzheimer's — albeit modestly. the drug can have serious side effects, such as brain swelling, s

lecanemab is not a wonder drug. mavis' short term memory remains badly affected. calculated lecanemab is likely to cost around £20,000 a year privately, but administering the drug and brain scans will probably double that, which the health assessment body, nice says does not represent value for money. you hold that for me, please? right. and i'll use this on your left, ok? there are dozens of similar drugs going through clinical trials. alzheimer's charities want the nhs to get ready for this new era of treatment. this is a defining moment for alzheimer's disease and gives us real hope for the future. but we have some big challenges ahead because the key to getting access to this treatment, or any potential future treatment, will be getting an early and accurate diagnosis. and we're nowhere near that at the moment. lecanemab can cause brain swelling and bleeding, so patients need careful monitoring. despite the risks and its modest benefits, many alzheimer's researchers regard lecanemab as a turning point because it shows this dreaded disease has its weaknesses an

lecanemab is designed to help clear the build—up of a toxic protein from the brain.. so this has been a long awaited decision and very unusually nice. the health assessment body for england and wales has come up with its decision to reject lecanemab at the same moment that the drug has been licensed, so it's been deemed safe and effective by the medicines regulator. so across the uk it will be available privately and will continue to be used in medical trials. but the sting in the tail is that the health assessment body says the benefits are just too small. when you set aside the costs that it would present to the nhs. and could you put that into perspective for us, this idea that the benefits are too small? it was seen as a breakthrough, though, wasn't it? well, it is, it is. and charities have said this is a defining moment and the reason why this is a big deal, this drug is there's never been a drug before in alzheimer's, which has convincingly slowed the progress of the disease. so lecanemab tackles the underlying mechanism, or one of the underlying mechanisms th

this new medicine, lecanemab, affects how quickly progresses.o assess those benefits and risks and usually they will discuss that with their doctor. but for most people this treatment, because of the associated scans and diagnostics that would need to be administered, will not be affordable for many and that is why it is so important that the government takes this seriously. brings people together and understands how we can make sure that the nhs is ready for the treatment of the future. one of the challenges we also have around the nice process is it doesn't value the true cost of dementia. it cost £a2 billion a year but the majority of those costs are not borne by the nhs, they are borne by individuals and theirfamilies. the nice process doesn't incorporate these costs into its assessment so i think that is one area that would need to be looked at in the future as well and alzheimer's research uk will be continuing to look at these issues. thank you very much for your time. there have been large falls in the number of work and student visas is

experts say the drug lecanemab , which is the first of lecanemab, which is the first of its kind, hasn shown to slow down the disease by almost 30%. the ruling means it can now be prescribed to private patients before a decision is made on whether to offer it to the nhs , whether to offer it to the nhs, and those are the latest gb news headlines. for now, i'm tatiana sanchez. more from me in half an hour for the very latest gb news direct to your smartphone, sign up to news alerts by scanning the qr code , or go to gbnews.com. >> slash alerts >> okay good afternoon britain britain britain. it is now 1238. now please do get your views in about this idea of some kind of youth mobility scheme with the european union . this is a bit of european union. this is a bit of a bit of free movement with europe that keir starmer is reportedly thinking about ministers. they've been talking to the guys in brussels deciding that perhaps this might be part of a reset with the european union. what do you make of that? anyone under 13 essentially can come to here work, to study, to have a nice time to d

would it be available lecanemab on private health care if you could afford it?out and seek? >> that's what it sounds like because it sounds like it has been, it has been given the go ahead for private prescriptions, but i don't know what the cost of that will be. i don't know if private healthcare insurance providers will cover the cost, because insurance companies have their own restrictions as well. so it's a little bit unclear at the moment, but there is that potential. i just want to add to that, that, even though you may think that anyone with alzheimer's is eligible for this, but there are still strict criteria as to who can access this. and at the moment it appears like it's those people with mild cognitive decline at the in the early stages of alzheimer's that are eligible. so those people that already have established alzheimer's disease probably wouldn't be eligible for it anyway necessarily benefit. >> okay. thank you. so much, gp doctor natalie rout there. if i walked into a gp surgery and i had that lovely smiley face, i would feel very reassured. l

lecanemab is designed to help clear the build—up of a toxic protein from the brain.e decline by about a quarter in patients in the early stages of the disease. but it won't be available on the nhs in england, due to the costs. let's speak to the alzheimer's society research grants manager, sian gregory. thank you very much forjoining us. first of all, how excited argue about this particular drug, and who it's for? i about this particular drug, and who it's for? ~ . about this particular drug, and who it's for? ,, . ., , it's for? i think what we are seeing is a defining _ it's for? i think what we are seeing is a defining moment _ it's for? i think what we are seeing is a defining moment in _ it's for? i think what we are seeing l is a defining moment in alzheimer's disease research. this is the first time we have ever seen a disease modifying treatment that tries to slow down the causes of the disease to be approved in the uk. so that is the payoff of decades of research that we first funded 30 years ago. we do know that the group of people that will benefit from th

is it lecanemab?ks, and then we'll get on to why you think it was turned down by the nhs ? nhs? >> well. hi, martin, thanks for having me on this drug. i mean, it's a defining moment because for the first time, we've got a drug which has been deemed safe and effective by one of the uk regulators. the mhra, to be deployed to patients. so it's a really defining, exciting moment. it's off the back of decades of research. what the drug actually does. this one is target and breaks down some toxic plaque that can develop in the brain cells of some people with alzheimer's disease, and it targets that to such an extent, andifs targets that to such an extent, and it's a relatively modest extent , that it slows down the extent, that it slows down the progression of the disease. and it's really exciting because it's really exciting because it's the first ever drug which has been demonstrated and then approved , which slows down the approved, which slows down the progression of alzheimer's disease, which as you s

experts say lecanemab, which is the first of its kind, has been shown to slow down the disease by almoste ruling means it can now be prescribed to private patients before a decision is made on whether to offer it on the nhs. >> four people who died in a house fire in bradford included three children. they've been named by police. 29 year old briony gawith died alongside nine year old dynasty five year old oscar and aubrey burtle, who was just 22 months old. a 39 year old man has been arrested at the scene on suspicion of murder and taken to hospital, where he remains in a critical condition . condition. >> and pop sensation taylor swift has spoken out for the first time since the vienna leg of her eras tour was cancelled. after that terror threat, she admitted she felt a new sense of fear and tremendous guilt after thousands of fans had already descended on vienna. it comes as she finished the european leg of her tour on tuesday night, breaking the record for the most wembley performances ever in one toun >>i toun >> iuked toun >> i liked what she said about that, actually . looking at h

mean time, so you may have seen the deeply encouraging news that the united kingdom has approved lecanemabe first ever alzheimer's drug that has been shown to slow cognitive decline by about 27%. the united states has approved the drug, too, but lo and behold, the european union has rejected this drug owing to concerns about side effects. it's ever present precautionary principle means that people can't get life saving treatments that will make their standard of living their experience in old age. so much better. why.7 when age. so much better. why? when people are suffering from alzheimer's, would the eu not allow patients who would be well informed of the side effects to at least try a new drug that is the first to be shown to delay some symptoms? because the european union is an overly regulated and overly risk averse institution , which we're lucky institution, which we're lucky to be out of. sir keir starmer whether he pursues a youth mobility agreement or not, clearly wants to pursue closer ties with the eu. but this decision from the eu regulator is a microcosm for why the prime min

so these drugs like lecanemab are working on very early stages, and your brain is amazing.e nhs will depend on what nice says, so it will depend on the risks and cost. 50 what nice says, so it will depend on the risks and cost.— the risks and cost. so that determination _ the risks and cost. so that determination is - the risks and cost. so that determination is yet - the risks and cost. so that determination is yet to i the risks and cost. so that determination is yet to be | the risks and cost. so that - determination is yet to be made? correct, although we are going to be talking to nice later on today, so hopefully we will hear more about that later on, but it is important to think that these drugs are not a cure and they have dangerous side effects, so that will weigh into the decision. ., ., ., , ., decision. you want to tell us a little more _ decision. you want to tell us a little more about _ decision. you want to tell us a little more about the - decision. you want to tell us a little more about the side - decision. you want to tell us a - little more about the si

so last week we had this really exciting a few days ago, we had this really exciting news about lecanemab now, another breakthrough drug , another breakthrough drug, donanemab, which is even more effective . it's a very, very, effective. it's a very, very, you know, exciting breakthrough at really slowing down alzheimer's. and guess what? both drugs are not going to be funded by the nhs . both drugs funded by the nhs. both drugs will cost between 20 and £30,000 a year at what cost? >> i mean, if you were a patient on it, it would cost you about 20 to 30 grand, between 20 to £30,000 on an animal. >> the latest one, the really good one, is around £25,000. so? so they're in. they're licensed for use in britain. they have been licensed but nicer saying that they're probably an insider as saying they're probably not going to get through because of the funding. the funding doesn't appear to be available on the nhs. and it's such a shame because we're all living longer. we all know people, you know, if we're not going to experience it. we all know parents, grandparents who are getting elderly, f